ACS Nano:纳米药物联合PEF成像将有助于提高癌症的靶向治疗

2016-10-31 MedSci MedSci原创

虽然纳米医学的发展已大大推进了癌症的个性化治疗,并减少了药物治疗潜在的副作用。但是目前仍难无法完全实现个性化治疗。近日,据发表于ACS Nano的一项新的研究取得了新的进展,可使得特定的抗癌药物在体内累积从而可更好的治疗患者。研究人员在动物体内测试了其药物载体——脂质纳米颗粒的效果。总所周知,个性化治疗十分复杂,正如人们所预料的那样,同一种药物会以不同的浓度在不同的肿瘤患者中积累,对于同一种癌症患

虽然纳米医学的发展已大大推进了癌症的个性化治疗,并减少了药物治疗潜在的副作用。但是目前仍难无法完全实现个性化治疗。近日,据发表于ACS Nano的一项新的研究取得了新的进展,可使得特定的抗癌药物在体内累积从而可更好的治疗患者。研究人员在动物体内测试了其药物载体——脂质纳米颗粒的效果。

众所周知,个性化治疗十分复杂,正如人们所预料的那样,同一种药物会以不同的浓度在不同的肿瘤患者中积累,对于同一种癌症患者同样也是如此。为了更好地评估哪些患者可受益于特定的纳米药物,如DOXIL或其他脂质体药物,这将有助于早期确定药物是否可以有效的药物浓度靶向肿瘤部位。

研究人员将常用于治疗骨转移的金属结合抗癌药物包裹在脂质体内。同样的方法将阿霉素包裹在脂质体内,这是另一个金属结合药物已广泛应用于肿瘤化疗和各种脂质体纳米药物中。然后可以使用正电子发射断层扫描(PET)来追踪药物在体内的走向。

乳腺癌卵巢癌小鼠模型成像显示,药物以不同的药物浓度在肿瘤和转移癌组织中积累,而且在大多数情况下,这些组织中药物浓度的水平高于正常组织中的水平。在同一个小鼠品系种,纳米药物竟然出现在子宫,这种情况下若不使用成像技术是无法追踪到此情况的。

该研究表明,联合PET成像或可有助于药物靶向癌组织的浓度及水平,以及纳米药物是否以有效治疗浓度达到靶向部位。

原始出处:

Imaging where cancer drugs go in the body could improve treatment. Science daily, October 26, 2016.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1997425, encodeId=3703199e4257c, content=<a href='/topic/show?id=bd828e850c1' target=_blank style='color:#2F92EE;'>#药物联合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87850, encryptionId=bd828e850c1, topicName=药物联合)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Sat Jul 29 04:19:00 CST 2017, time=2017-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804601, encodeId=887d180460124, content=<a href='/topic/show?id=20cae745155' target=_blank style='color:#2F92EE;'>#纳米药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77451, encryptionId=20cae745155, topicName=纳米药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Mon Dec 12 14:19:00 CST 2016, time=2016-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726230, encodeId=dba91e262307a, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Nov 24 01:19:00 CST 2016, time=2016-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155029, encodeId=3e501550291a, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Nov 11 14:44:32 CST 2016, time=2016-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=154106, encodeId=9f501541069d, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Mon Nov 07 16:10:24 CST 2016, time=2016-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279139, encodeId=788312e9139fe, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Wed Nov 02 02:19:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475668, encodeId=f3d314e566842, content=<a href='/topic/show?id=cbcce745264' target=_blank style='color:#2F92EE;'>#纳米药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77452, encryptionId=cbcce745264, topicName=纳米药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a11c7248108, createdName=xugc, createdTime=Wed Nov 02 02:19:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152408, encodeId=68f215240883, content=好好看下, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Oct 31 16:06:13 CST 2016, time=2016-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152387, encodeId=143215238ee2, content=不错,学习了,顶顶!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c10c75714, createdName=zhuzhuba1, createdTime=Mon Oct 31 14:56:33 CST 2016, time=2016-10-31, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1997425, encodeId=3703199e4257c, content=<a href='/topic/show?id=bd828e850c1' target=_blank style='color:#2F92EE;'>#药物联合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87850, encryptionId=bd828e850c1, topicName=药物联合)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Sat Jul 29 04:19:00 CST 2017, time=2017-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804601, encodeId=887d180460124, content=<a href='/topic/show?id=20cae745155' target=_blank style='color:#2F92EE;'>#纳米药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77451, encryptionId=20cae745155, topicName=纳米药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Mon Dec 12 14:19:00 CST 2016, time=2016-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726230, encodeId=dba91e262307a, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Nov 24 01:19:00 CST 2016, time=2016-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155029, encodeId=3e501550291a, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Nov 11 14:44:32 CST 2016, time=2016-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=154106, encodeId=9f501541069d, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Mon Nov 07 16:10:24 CST 2016, time=2016-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279139, encodeId=788312e9139fe, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Wed Nov 02 02:19:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475668, encodeId=f3d314e566842, content=<a href='/topic/show?id=cbcce745264' target=_blank style='color:#2F92EE;'>#纳米药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77452, encryptionId=cbcce745264, topicName=纳米药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a11c7248108, createdName=xugc, createdTime=Wed Nov 02 02:19:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152408, encodeId=68f215240883, content=好好看下, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Oct 31 16:06:13 CST 2016, time=2016-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152387, encodeId=143215238ee2, content=不错,学习了,顶顶!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c10c75714, createdName=zhuzhuba1, createdTime=Mon Oct 31 14:56:33 CST 2016, time=2016-10-31, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1997425, encodeId=3703199e4257c, content=<a href='/topic/show?id=bd828e850c1' target=_blank style='color:#2F92EE;'>#药物联合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87850, encryptionId=bd828e850c1, topicName=药物联合)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Sat Jul 29 04:19:00 CST 2017, time=2017-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804601, encodeId=887d180460124, content=<a href='/topic/show?id=20cae745155' target=_blank style='color:#2F92EE;'>#纳米药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77451, encryptionId=20cae745155, topicName=纳米药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Mon Dec 12 14:19:00 CST 2016, time=2016-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726230, encodeId=dba91e262307a, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Nov 24 01:19:00 CST 2016, time=2016-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155029, encodeId=3e501550291a, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Nov 11 14:44:32 CST 2016, time=2016-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=154106, encodeId=9f501541069d, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Mon Nov 07 16:10:24 CST 2016, time=2016-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279139, encodeId=788312e9139fe, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Wed Nov 02 02:19:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475668, encodeId=f3d314e566842, content=<a href='/topic/show?id=cbcce745264' target=_blank style='color:#2F92EE;'>#纳米药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77452, encryptionId=cbcce745264, topicName=纳米药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a11c7248108, createdName=xugc, createdTime=Wed Nov 02 02:19:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152408, encodeId=68f215240883, content=好好看下, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Oct 31 16:06:13 CST 2016, time=2016-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152387, encodeId=143215238ee2, content=不错,学习了,顶顶!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c10c75714, createdName=zhuzhuba1, createdTime=Mon Oct 31 14:56:33 CST 2016, time=2016-10-31, status=1, ipAttribution=)]
    2016-11-24 feather89
  4. [GetPortalCommentsPageByObjectIdResponse(id=1997425, encodeId=3703199e4257c, content=<a href='/topic/show?id=bd828e850c1' target=_blank style='color:#2F92EE;'>#药物联合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87850, encryptionId=bd828e850c1, topicName=药物联合)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Sat Jul 29 04:19:00 CST 2017, time=2017-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804601, encodeId=887d180460124, content=<a href='/topic/show?id=20cae745155' target=_blank style='color:#2F92EE;'>#纳米药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77451, encryptionId=20cae745155, topicName=纳米药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Mon Dec 12 14:19:00 CST 2016, time=2016-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726230, encodeId=dba91e262307a, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Nov 24 01:19:00 CST 2016, time=2016-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155029, encodeId=3e501550291a, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Nov 11 14:44:32 CST 2016, time=2016-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=154106, encodeId=9f501541069d, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Mon Nov 07 16:10:24 CST 2016, time=2016-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279139, encodeId=788312e9139fe, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Wed Nov 02 02:19:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475668, encodeId=f3d314e566842, content=<a href='/topic/show?id=cbcce745264' target=_blank style='color:#2F92EE;'>#纳米药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77452, encryptionId=cbcce745264, topicName=纳米药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a11c7248108, createdName=xugc, createdTime=Wed Nov 02 02:19:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152408, encodeId=68f215240883, content=好好看下, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Oct 31 16:06:13 CST 2016, time=2016-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152387, encodeId=143215238ee2, content=不错,学习了,顶顶!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c10c75714, createdName=zhuzhuba1, createdTime=Mon Oct 31 14:56:33 CST 2016, time=2016-10-31, status=1, ipAttribution=)]
    2016-11-11 李东泽

    很好,不错,以后会多学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1997425, encodeId=3703199e4257c, content=<a href='/topic/show?id=bd828e850c1' target=_blank style='color:#2F92EE;'>#药物联合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87850, encryptionId=bd828e850c1, topicName=药物联合)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Sat Jul 29 04:19:00 CST 2017, time=2017-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804601, encodeId=887d180460124, content=<a href='/topic/show?id=20cae745155' target=_blank style='color:#2F92EE;'>#纳米药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77451, encryptionId=20cae745155, topicName=纳米药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Mon Dec 12 14:19:00 CST 2016, time=2016-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726230, encodeId=dba91e262307a, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Nov 24 01:19:00 CST 2016, time=2016-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155029, encodeId=3e501550291a, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Nov 11 14:44:32 CST 2016, time=2016-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=154106, encodeId=9f501541069d, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Mon Nov 07 16:10:24 CST 2016, time=2016-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279139, encodeId=788312e9139fe, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Wed Nov 02 02:19:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475668, encodeId=f3d314e566842, content=<a href='/topic/show?id=cbcce745264' target=_blank style='color:#2F92EE;'>#纳米药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77452, encryptionId=cbcce745264, topicName=纳米药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a11c7248108, createdName=xugc, createdTime=Wed Nov 02 02:19:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152408, encodeId=68f215240883, content=好好看下, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Oct 31 16:06:13 CST 2016, time=2016-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152387, encodeId=143215238ee2, content=不错,学习了,顶顶!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c10c75714, createdName=zhuzhuba1, createdTime=Mon Oct 31 14:56:33 CST 2016, time=2016-10-31, status=1, ipAttribution=)]
    2016-11-07 李东泽

    很好,不错,以后会多学习

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1997425, encodeId=3703199e4257c, content=<a href='/topic/show?id=bd828e850c1' target=_blank style='color:#2F92EE;'>#药物联合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87850, encryptionId=bd828e850c1, topicName=药物联合)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Sat Jul 29 04:19:00 CST 2017, time=2017-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804601, encodeId=887d180460124, content=<a href='/topic/show?id=20cae745155' target=_blank style='color:#2F92EE;'>#纳米药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77451, encryptionId=20cae745155, topicName=纳米药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Mon Dec 12 14:19:00 CST 2016, time=2016-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726230, encodeId=dba91e262307a, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Nov 24 01:19:00 CST 2016, time=2016-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155029, encodeId=3e501550291a, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Nov 11 14:44:32 CST 2016, time=2016-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=154106, encodeId=9f501541069d, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Mon Nov 07 16:10:24 CST 2016, time=2016-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279139, encodeId=788312e9139fe, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Wed Nov 02 02:19:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475668, encodeId=f3d314e566842, content=<a href='/topic/show?id=cbcce745264' target=_blank style='color:#2F92EE;'>#纳米药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77452, encryptionId=cbcce745264, topicName=纳米药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a11c7248108, createdName=xugc, createdTime=Wed Nov 02 02:19:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152408, encodeId=68f215240883, content=好好看下, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Oct 31 16:06:13 CST 2016, time=2016-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152387, encodeId=143215238ee2, content=不错,学习了,顶顶!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c10c75714, createdName=zhuzhuba1, createdTime=Mon Oct 31 14:56:33 CST 2016, time=2016-10-31, status=1, ipAttribution=)]
    2016-11-02 yaanren
  7. [GetPortalCommentsPageByObjectIdResponse(id=1997425, encodeId=3703199e4257c, content=<a href='/topic/show?id=bd828e850c1' target=_blank style='color:#2F92EE;'>#药物联合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87850, encryptionId=bd828e850c1, topicName=药物联合)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Sat Jul 29 04:19:00 CST 2017, time=2017-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804601, encodeId=887d180460124, content=<a href='/topic/show?id=20cae745155' target=_blank style='color:#2F92EE;'>#纳米药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77451, encryptionId=20cae745155, topicName=纳米药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Mon Dec 12 14:19:00 CST 2016, time=2016-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726230, encodeId=dba91e262307a, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Nov 24 01:19:00 CST 2016, time=2016-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155029, encodeId=3e501550291a, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Nov 11 14:44:32 CST 2016, time=2016-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=154106, encodeId=9f501541069d, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Mon Nov 07 16:10:24 CST 2016, time=2016-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279139, encodeId=788312e9139fe, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Wed Nov 02 02:19:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475668, encodeId=f3d314e566842, content=<a href='/topic/show?id=cbcce745264' target=_blank style='color:#2F92EE;'>#纳米药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77452, encryptionId=cbcce745264, topicName=纳米药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a11c7248108, createdName=xugc, createdTime=Wed Nov 02 02:19:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152408, encodeId=68f215240883, content=好好看下, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Oct 31 16:06:13 CST 2016, time=2016-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152387, encodeId=143215238ee2, content=不错,学习了,顶顶!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c10c75714, createdName=zhuzhuba1, createdTime=Mon Oct 31 14:56:33 CST 2016, time=2016-10-31, status=1, ipAttribution=)]
    2016-11-02 xugc
  8. [GetPortalCommentsPageByObjectIdResponse(id=1997425, encodeId=3703199e4257c, content=<a href='/topic/show?id=bd828e850c1' target=_blank style='color:#2F92EE;'>#药物联合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87850, encryptionId=bd828e850c1, topicName=药物联合)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Sat Jul 29 04:19:00 CST 2017, time=2017-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804601, encodeId=887d180460124, content=<a href='/topic/show?id=20cae745155' target=_blank style='color:#2F92EE;'>#纳米药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77451, encryptionId=20cae745155, topicName=纳米药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Mon Dec 12 14:19:00 CST 2016, time=2016-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726230, encodeId=dba91e262307a, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Nov 24 01:19:00 CST 2016, time=2016-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155029, encodeId=3e501550291a, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Nov 11 14:44:32 CST 2016, time=2016-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=154106, encodeId=9f501541069d, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Mon Nov 07 16:10:24 CST 2016, time=2016-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279139, encodeId=788312e9139fe, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Wed Nov 02 02:19:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475668, encodeId=f3d314e566842, content=<a href='/topic/show?id=cbcce745264' target=_blank style='color:#2F92EE;'>#纳米药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77452, encryptionId=cbcce745264, topicName=纳米药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a11c7248108, createdName=xugc, createdTime=Wed Nov 02 02:19:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152408, encodeId=68f215240883, content=好好看下, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Oct 31 16:06:13 CST 2016, time=2016-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152387, encodeId=143215238ee2, content=不错,学习了,顶顶!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c10c75714, createdName=zhuzhuba1, createdTime=Mon Oct 31 14:56:33 CST 2016, time=2016-10-31, status=1, ipAttribution=)]
    2016-10-31 忠诚向上

    好好看下

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1997425, encodeId=3703199e4257c, content=<a href='/topic/show?id=bd828e850c1' target=_blank style='color:#2F92EE;'>#药物联合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87850, encryptionId=bd828e850c1, topicName=药物联合)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Sat Jul 29 04:19:00 CST 2017, time=2017-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804601, encodeId=887d180460124, content=<a href='/topic/show?id=20cae745155' target=_blank style='color:#2F92EE;'>#纳米药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77451, encryptionId=20cae745155, topicName=纳米药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Mon Dec 12 14:19:00 CST 2016, time=2016-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726230, encodeId=dba91e262307a, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Nov 24 01:19:00 CST 2016, time=2016-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155029, encodeId=3e501550291a, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Nov 11 14:44:32 CST 2016, time=2016-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=154106, encodeId=9f501541069d, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Mon Nov 07 16:10:24 CST 2016, time=2016-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279139, encodeId=788312e9139fe, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Wed Nov 02 02:19:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475668, encodeId=f3d314e566842, content=<a href='/topic/show?id=cbcce745264' target=_blank style='color:#2F92EE;'>#纳米药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77452, encryptionId=cbcce745264, topicName=纳米药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a11c7248108, createdName=xugc, createdTime=Wed Nov 02 02:19:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152408, encodeId=68f215240883, content=好好看下, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Oct 31 16:06:13 CST 2016, time=2016-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152387, encodeId=143215238ee2, content=不错,学习了,顶顶!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c10c75714, createdName=zhuzhuba1, createdTime=Mon Oct 31 14:56:33 CST 2016, time=2016-10-31, status=1, ipAttribution=)]
    2016-10-31 zhuzhuba1

    不错,学习了,顶顶!

    0

相关资讯

何鼎:癌症治疗迈入新阶段

以纳米技术为基础的治疗药物将为癌症治疗带来一场革命。日前,加州大学洛杉矶分校UCLA的著名美籍华裔教授何鼎(Dean Ho),在The Scientist杂志上撰写文章介绍了用纳米药物对抗癌症的最新进展。传统的癌症治疗方式主要面临着两个挑战,药物循环时间短和难以对肿瘤位点进行局部治疗。除此之外,癌症药物的毒性和肿瘤演化出的抗性,也一直令医生们头疼不已。癌症药物的毒性可能引起严重的并发症,例如白细胞

Cancer Res:纳米药物新组合有望解决乳腺癌耐药问题

近日,来自加拿大多伦多Sunnybrook研究所的研究人员在国际学术期刊Cancer Research上发表了一项最新研究进展,他们发现将一种纳米颗粒化疗药物与抗血管生成药物联合使用能够有效治疗乳腺癌。 将bevacizumab等靶向VEGF信号途径的抗血管生成药物与化疗药物结合使用改变了对多种人类乳腺癌的临床治疗实践。但是在治疗过程中经常会产生适应性耐药,其中一个主要机制在于肿瘤内部低氧环境

Adv Mater:基于荧光碳点的诊断治疗纳米药物研究获进展

近日,中国科学院长春光学精密机械与物理研究所孙再成研究小组和中国科学院长春应用化学研究所的谢志刚和景遐斌课题组合作开发了基于荧光碳点的诊断治疗纳米药物,为实现个性化治疗奠定了基础,相关成果发表在《先进材料》上(Min Zheng et al. Adv. Mater. DOI: 10.1002/adma. 201306192)。 诊断治疗药物是能够将治疗和诊断功能集成在一起的新型纳米药物,它将成像